The quantification of circular RNA 0007841 during induction therapy helps estimate the response and survival benefits to bortezomib-based regimen in multiple myeloma

Guo, Yi; Feng, Xianrong; Wang, Zhen; Zhang, Ruibo; Zheng, Kun; Xu, Jinyun; Hu, Ping; Zhang, Rongyao

doi:10.1007/s11845-023-03410-w

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports showed that circ_0007841 plays a key role in tumorigenesis, including multiple myeloma, NSCLC and ovarian Frontiers in Genetics frontiersin.org cancer (Wang et al, 2020d;Huang et al, 2021;Long et al, 2022;Guo et al, 2023). Long et al reported that circ_0007841 took part in tumor progression via regulation of miR-199a-5p/SphK2 axis (Long et al, 2022).…”

Section: Circ_0007841mentioning

confidence: 99%

The role of circRNAs in regulation of drug resistance in ovarian cancer

Zhan,

Li,

Lin

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Ovarian cancer is one of the female reproductive system tumors. Chemotherapy is used for advanced ovarian cancer patients; however, drug resistance is a pivotal cause of chemotherapeutic failure. Hence, it is critical to explore the molecular mechanisms of drug resistance of ovarian cancer cells and to ameliorate chemoresistance. Noncoding RNAs (ncRNAs) have been identified to critically participate in drug sensitivity in a variety of human cancers, including ovarian cancer. Among ncRNAs, circRNAs sponge miRNAs and prevent miRNAs from regulation of their target mRNAs. CircRNAs can interact with DNA or proteins to modulate gene expression. In this review, we briefly describe the biological functions of circRNAs in the development and progression of ovarian cancer. Moreover, we discuss the underneath regulatory molecular mechanisms of circRNAs on governing drug resistance in ovarian cancer. Furthermore, we mention the novel strategies to overcome drug resistance via targeting circRNAs in ovarian cancer. Due to that circRNAs play a key role in modulation of drug resistance in ovarian cancer, targeting circRNAs could be a novel approach for attenuation of chemoresistance in ovarian cancer.

show abstract